BTK and COVID-19: In humans, effective suppression of the NLRP3/IL-1 axis by BTK inhibitors, and thus a positive regulatory effect of BTK on NLRP3, was instead suggested by a recent off-label trial of acalabrutinib in COVID-19 patients (Roschewski et al., 2020).